Raludotatug deruxtecan for PARP-inhibitor-resistant ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called raludotatug deruxtecan (with or without bevacizumab) for people with ovarian cancer that has grown despite PARP inhibitor maintenance treatment. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a common type of ovarian cancer called high-grade serous or high-grade endometrioid (can also be in the fallopian tubes or lining of the belly).
- You have had only one line of platinum-based chemotherapy (like carboplatin or cisplatin), and your cancer came back more than 6 months after that treatment.
- You took a PARP inhibitor (like olaparib, niraparib, or rucaparib) as maintenance therapy after your first chemo, and your cancer grew during that treatment or within 6 weeks of stopping it.
- You are generally able to take care of yourself (doctors call this performance status 0 or 1).
- You have recovered from any side effects of your previous treatments.
- You do not have other types of ovarian cancer (like clear cell, mucinous, or borderline), serious bleeding or clotting problems, severe lung disease, bowel obstruction, or another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
This study tests a new investigational drug, raludotatug deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as maintenance treatment after second-line platinum-based chemotherapy for recurrent ovarian cancer. The goal is to keep the cancer from growing longer.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This study tests a new drug called raludotatug deruxtecan for people with certain types of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is designed to target and kill cancer cells while sparing healthy tissue. It may be used alone or with other treatments, depending on the study group.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.